Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Pittsburgh compound B Stories

2013-11-11 21:27:19

Patients with traumatic brain injury (TBI) had increased deposits of β-Amyloid (Aβ) plaques, a hallmark of Alzheimer Disease (AD), in some areas of their brains in a study by Young T. Hong, Ph.D., of the University of Cambridge, England, and colleagues. There may be epidemiological or pathophysiological (changes because of injury) links between TBI and AD, and Aβ plaques are found in as many as 30 percent of patients who die in the acute phase after a TBI. The plaques appear within...

2013-10-07 08:25:05

MONTREAL, Oct. 7, 2013 /CNW/ - Results from two new studies add to the body of evidence that supports Cognigram(TM) as a sensitive assessment to detect and monitor cognitive decline over time, namely in healthy individuals and adults with mild cognitive impairment (MCI) that are carriers of a biological marker in the brain - Ab amyloid.(1,2) Data from two studies were presented at the Canadian Conference on Dementia (CCD), in Vancouver, British Columbia, between October 3 and 5....

2013-09-30 12:27:14

- Alzheimer's Association Statement - WASHINGTON, Sept. 30, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Association is disappointed by the Centers for Medicare & Medicaid Services (CMS) decision to only allow Coverage with Evidence Development (CED) for an Alzheimer's imaging test that would improve diagnostic accuracy and certainty in challenging cases. When used in specific populations, as outlined in criteria developed by the Alzheimer's Association and the Society for Nuclear...

2013-07-19 00:21:21

CHICAGO, July 19, 2013 /PRNewswire-USNewswire/ -- A global, collaborative research effort based on public-private partnerships, similar to the projects in the 1950s and 1960s that successfully reduced polio worldwide, will be essential in advancing the prevention, diagnosis, and treatment of Alzheimer's disease, according to two articles written by leaders of the Alzheimer's Association and published in the July 2013 issue of Alzheimer's & Dementia: The Journal of the Alzheimer's...

2013-07-05 12:23:10

- Alzheimer's Association Statement - CHICAGO, July 5, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Association is disappointed by the Centers for Medicare & Medicaid Services (CMS) draft coverage decision on brain amyloid imaging, particularly given the clear, scientific consensus recommendations provided to CMS by the Association and the Society for Nuclear Medicine and Molecular Imaging (SNMMI) regarding appropriate, limited coverage, only in specific populations. The...

2013-06-11 14:53:38

Healthy test subjects with amyloid plaque were also found to have hypometabolism indicating a potential Alzheimer´s precursor Alzheimer´s disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer´s disease–even for people with no sign of cognitive decline. This is a new...

2013-01-30 20:22:35

- Alzheimer's Association Statement - WASHINGTON, Jan. 30, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Association is disappointed that the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) panel does not believe that there is adequate evidence whether or not PET imaging of brain beta amyloid changes health outcomes, and urges the Centers for Medicare & Medicaid Service (CMS) to review the evidence and make a positive determination about coverage. The...

2013-01-30 20:22:31

INDIANAPOLIS, Jan. 30, 2013 /PRNewswire/ -- Leading medical experts in the fields of imaging, neurology and dementia came together today to present evidence supporting the clinical utility of beta-amyloid imaging agents, such as Amyvid(TM) (Florbetapir F 18 Injection), during a public hearing held by the Centers for Medicare & Medicaid Services (CMS), known as a Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting. The CMS panel voted "low to intermediate...

2012-10-19 11:23:36

INDIANAPOLIS, Oct. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, recommending approval of Amyvid (Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of...

2012-08-13 02:25:25

BALTIMORE, Aug. 13, 2012 /PRNewswire/ -- American Radiology Services (ARS), a division of RadNet, Inc., a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 237 fully-owned and operated outpatient imaging centers, announced it will offer Amyvid(TM), a radioactive tracer used in positron emission tomography-computed tomography (PET/CT) imaging. Amyvid is the first test that can effectively rule out Alzheimer's disease (AD) in patients...